# US 2001/0022962 A1 · Cellulose diacetate compositions for use in embolizing blood vessels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0022962 A1
- Document ID: US20010022962A1
- Status: Published application
- Kind: A1
- Application number: 09/766,540
- Filed: 2001-01-18
- Published: 2001-09-20
- Earliest claimed: 1996-07-29
- Inventors: Richard J. Greff; Michael L. Jones; Scott Evans
- Web page: https://patentgrep.com/patent/US20010022962A1

## CPC

- A61K 31/717: Celluloses
- A61K 49/0404: {containing barium sulfate}
- A61K 49/0409: {Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound}
- C08L 1/12: Cellulose acetate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Disclosed are compositions suitable for use in embolizing blood vessels which compositons comprise a cellulose diacetate polymer, a biocompatible solvent and a water insoluble contrasting agent selected from the group consisting of tantalum, tantalum oxide, and barium sulfate. Also disclosed are methods for embloizing a blood vessel using the compositins described herein.

## Claims

### Claim 1

A composition comprising:
(a) from about 2.5 to about 8 weight percent of a cellulose diacetate having an acetyl content of from about 31 to about 40 weight percent;
(b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
(c) from about 52 to about 87.5 weight percent of a biocompatible solvent
wherein the weight percent of the cellulose acetate, water insoluble contrast agent and biocompatible solvent is based on the total weight of the complete composition.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein said cellulose diacetate comprises about 39.8 weight percent acetyl content.

### Claim 3 (depends on 2)

The composition according to claim 2 wherein said biocompatible solvent is DMSO.

### Claim 4 (depends on 3)

The composition according to claim 3 wherein said contrast agent is tantalum.

### Claim 5 (depends on 3)

The composition according to claim 3 wherein said contrast agent is tantalum oxide.

### Claim 6 (depends on 3)

The composition according to claim 3 wherein said contrast agent is barium sulfate.

### Claim 7

A method for embolizing a blood vessel by injecting into said blood vessel a sufficient amount of an embolizing composition comprising:
(a) from about 2.5 to about 8 weight percent of a cellulose diacetate embolizing agent wherein said cellulose diacetate has an acetyl content of from about 31 to about 40 weight percent;
(b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
(c) from about 52 to about 87.5 weight percent of a biocompatible solvent
wherein the weight percent of the cellulose acetate, water insoluble contrast agent and biocompatible solvent is based on the total weight of the complete composition
under conditions wherein a precipitate is formed which embolizes the blood vessel.

### Claim 8 (depends on 7)

The method according to claim 7 wherein said cellulose diacetate polymer comprises about 39.8 weight percent acetyl content.

### Claim 9 (depends on 8)

The method according to claim 8 wherein said biocompatible solvent is DMSO.

### Claim 10 (depends on 9)

The method according to claim 9 wherein said contrast agent is tantalum.

### Claim 11 (depends on 9)

The method according to claim 9 wherein said contrast agent is tantalum oxide.

### Claim 12 (depends on 9)

The method according to claim 9 wherein said contrast agent is barium sulfate.

### Claim 13 (depends on 7)

The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of about 0.05 to 0.3 cc/minute.

### Claim 14 (depends on 7)

The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of at least 0.6 cc/minute.

### Claim 15 (depends on 14)

The method according to claim 14 wherein the injection rate of at least 0.6 cc/minute is employed to form a filament like mass projecting down stream from the catheter tip for embolizing tumor masses, organs and arteriovenous malformations (AVM).
